XenoPort up on XP19986 data

XenoPort Inc. (NASDAQ:XNPT) gained $1.51 to $23.17 on Tuesday after reporting that two out of three doses of arbaclofen placarbil ( XP19986) met the primary endpoint in a Phase II trial to treat spast...